They

PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/609,132 TRANSMITTAL Filing Date June 26, 2003 **FORM** First Named Inventor Andrew J. BOECKLE, et al. Art Unit 3721 **Examiner Name** Louis K. HUYNH (to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	Attorney Docket Number 0133.0	0				
	ENCLOSURES (OLIVERAL)					
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request X Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please Identify below): European Search Report (copy); Form PTO/SB/08A; 2 Cited References; and Return Receipt Postcard				
SIGNA	TURE OF APPLICANT, ATTORNEY, (OR AGENT				
NEKTAR THERAPEUTICS						
Signature May Varle						
Printed name Guy V. Tucker						
Date 28 JUN 200 6 Reg. No. 45,302						
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature	a Cotta					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Minna Cotter

Typed or printed name

Date

06/28/2006

PATENT

JUN 3.0 2006 JUN 3

In re the application of: Andrew J. BOECKLE, et al.

Atty. Docket No.: 0133.00

Examiner: Louis K. HUYNH

Application No.: 10/609,132

Filed: 06/26/2003

Title: CONTROLLING THE FLOW OF A POWDER

POWDER

Atty. Docket No.: 0133.00

Converted No.: 0133.00

Examiner: Louis K. HUYNH

Ofroup Art Unit: 3721

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on June 28, 2006

Signed: /

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Form PTO/SB/08A may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

In compliance with 37 CFR §§1.98 (2) enclosed are copies of each foreign patent; other than U.S. patent application publications, unless required by the Office.

filed:	inis i	niormation Disc	closure Statement is being timely filed under 37 CFR §§1.97 and is being
		months of the international a	nonths of the filing date of a national application or an RCE; within three date of entry of the national stage as set forth in section 1.491 in an application; or before the mailing date of a first Office action on the ever event occurs last);
		of a first Office under section	the months from the filing date of an application and after the mailing date be action on the merits, but before the mailing date of either a final action 1.113 or a notice of allowance under section 1.311 (whichever occurs accompanied by: the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or one of the following statements as specified in 37 CFR 1.97(e) that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or
			Ing date of either a final action under section 1.113 or a notice of ler section 1.311, but on or before the payment of the issue fee, and is by each of: the following petition: Applicant hereby requests consideration of the accompanying information disclosure statement; the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and one of the following statements as specified in 37 CFR 1.97(e) that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three

			s prior to the filing of the information disclosure nent; or
		office of the inquir disclos	m of information contained in the information disclosure tent was cited in a communication from a foreign patent in a counterpart foreign application, and, to the knowledge person signing the statement after making reasonable y, no item of information contained in the information sure statement was known to any individual designated in 1.56(c) more than three months prior to the filing of the nation disclosure statement.
	a communicate this communicate this communicate more than thire statement. Acconstitute a factor conclude present to conclude present the communicate this commu	cation from cation was ty days ccordin ilure or cosecuti	within this Information Disclosure Statement was cited in m a foreign patent office in a counterpart application and was not received by any individual designated in 1.56(c) prior to the filing of the Information Disclosure gly, this Information Disclosure Statement does not a the part of the Applicant to engage in reasonable efforts on of the application as set forth in 37 CFR 1.704 of adjustment of patent term."
	Attached is Check No in th	ne amou	unt of <u>\$0</u> .
	Please charge the amount of	\$	to Deposit Account 500348
	If it is determined that any ad charge such fees to Deposit A		I fees are due, the Commissioner is hereby authorized to 500348.
			Respectfully submitted,
Dated:	2B. WN 2006	Ву:	NEKTAR THERAPEUTICS Juy Guy V./Tucker Reg. No. 45,302
150 Inc San Ca	AR THERAPEUTICS lustrial Road rlos, CA 94070 20-5501		

Form PTO/SB/08A (Modified)

JUN 3.0 2006

Information Disclosure Statement By Applicant

(Use Several Sheets if Necessary)

Atty Docket No.:	Application No.:
0133.00	10/609,132
Applicant:	
Andrew J. B	OECKLE, et al.
Filing Date:	Group:
06/26/2003	3721

U.S. Patent Documents

Examiner						Sub-	Filing
Initial		Patent No.	Date	Patentee	Class	Class	Date
·	A	2002/056206	05/16/2002	Pace et al.			
	В	2002/076382	06/20/2002	Kaplan et al.	 		
_				•			
, , <u>, , , , , , , , , , , , , , , , , </u>							
					<u>-</u>		
							-

					1		
					<u> </u>		
	-						
	ļ						
	-						
	<u> </u>						
						-	
							
							
							
					<u> </u>		
					-		
	-		<u> </u>		 		
	L	L		l	l		

Examiner:	Date Considered:

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO/SB/08B (Modified)	Atty Docket No.:	Application No.:
Information Disclosure Statement By Applicant	Applicant:	
(Use Several Sheets if Necessary)	Filing Date:	Group:

Other Documents

Examiner								
Initial	No.		Author, Title, Date, Place (e.g. Journal) of Publication					
	C	99/19215	04/22/1999	wo				
	D	01/72605	10/04/2001	wo				
							_	
						İ		
			-					
					1	1		
					7.			
]			
								<u> </u>
							-	
					<u> </u>	 	-	
							_	
						 		
			-					 -

Examiner:	Date Considered:

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.